Theratechnologies (NASDAQ:THTX - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08), Zacks reports. The company had revenue of $17.73 million for the quarter, compared to the consensus estimate of $24.30 million.
Theratechnologies Price Performance
THTX stock remained flat at $3.14 during mid-day trading on Wednesday. 914,094 shares of the company's stock traded hands, compared to its average volume of 886,857. The company has a market capitalization of $144.38 million, a P/E ratio of -39.25 and a beta of 0.55. Theratechnologies has a 1-year low of $1.12 and a 1-year high of $3.20. The firm's 50-day moving average price is $2.62 and its 200-day moving average price is $2.08.
Wall Street Analysts Forecast Growth
Separately, Jones Trading cut shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.
Read Our Latest Stock Analysis on Theratechnologies
Institutional Trading of Theratechnologies
An institutional investor recently bought a new position in Theratechnologies stock. Acadian Asset Management LLC purchased a new stake in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 28,400 shares of the company's stock, valued at approximately $39,000. Acadian Asset Management LLC owned approximately 0.06% of Theratechnologies as of its most recent SEC filing.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Further Reading
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
